By combining the common variant common disease and rare variant common disease hypotheses [103–105], the idea of mutational burden emerges as a prognostic/diagnostic alternative for AMD, as exemplified by both common and rare variants in AP inhibitors leading to pathogenic dysregulated AP activity (Table 4). Here, DHCR7-DT is linked to age-related macular degeneration.